Table 2 The targeting integrin-related indications in clinical trials
From: Targeting integrin pathways: mechanisms and advances in therapy
Indication | Target in clinical research |
|---|---|
Ulcerative colitis and Crohn’s disease | α4β7; α4β1; αEβ7; α2β1 |
Multiple sclerosis | α4β7; α4β1; α2β1 |
Acute coronary syndrome and thrombotic cardiovascular events | αIIbβ3; α4β1 |
Plaque psoriasis | αvβ3; Integrin α; α4β1; αLβ2 |
Rheumatoid arthritis | α1β1; α9β1; αvβ3 |
Cancers | Pan-αv; α5β1; α2; αLβ2; α4β1; β6; α3β1; β7 |
Diabetic nephropathy | αvβ3 |
Interstitial fibrosis and tubular atrophy; idiopathic pulmonary fibrosis | Pan-αv |
HIV | α4β7; LFA-1A; α4β1 |
SARS-CoV-2 | αvβ1; αvβ6 |
Dry eye disease | LFA-1; α4 |
Symptomatic focal vitreomacular adhesion; diabetic macular edema; non-proliferative diabetic retinopathy; non-exudative macular degeneration; age-related macular degeneration | Pan-αv; α2β1; α4β1; α5β1 |
Patellar osteoarthritis involving both knees; patellofemoral osteoarthritis involving both knees | Pan-αv; α4β1 |
Asthma | α4β1; α4β7 |
Imaging agent | αvβ3; αvβ5; αvβ6; α6; αIIbβ3; |
Leukocyte adhesion deficiency-I | β2 |
